ABOUT US
STRATEGY
Amarin’s primary focus is to develop AMR101 for the treatment of hypertriglyceridemia in patients with very high triglycerides, and for the treatment of high triglycerides in patients with mixed dyslipidemia who are taking statins. Amarin will progress the clinical program through submission of a New Drug Application to the FDA. Amarin will partner with a larger pharmaceutical company to commercialize AMR101 for hypertriglyceridemia and related cardiovascular diseases in the US and in other territories.
This page was last updated on March 04, 2010
